



Published in final edited form as:

J Immunol. 2022 August 01; 209(3): 526–534. doi:10.4049/jimmunol.2101211.

T helper 2-biased transcriptional profile predicts HIV envelope-specific polyfunctional CD4⁺ T cells that correlated with reduced risk of infection in RV144 trial

Kristen W. Cohen^{*}, Yuan Tian[†], Casey Thayer^{*}, Aaron Seese^{*}, Robert Amezcua^{‡,†}, M. Juliana McElrath^{*§}, Stephen C. De Rosa^{*§}, Raphael Gottardo^{†,¶,||}

^{*}Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

[‡]Biostatistics, Bioinformatics and Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

[†]Current address: Pfizer, La Jolla, CA, USA

[§]Departments of Laboratory Medicine and Medicine, University of Washington, Seattle, WA 98107, USA

[¶]Current address: Biomedical Data Sciences Center, Lausanne University Hospital, Lausanne, Vaud, Switzerland

Abstract

Antigen-specific T cells play a critical role in responding to viral infections. In the RV144 HIV vaccine clinical trial, a rare subset of HIV-specific polyfunctional CD4⁺ T cells correlated with reduced risk of HIV-1 infection. Polyfunctional T cells are a subset of antigen-specific T cells which are able to simultaneously produce multiple effector cytokines. Little is known about what differentiates polyfunctional T cells from other vaccine-elicited T cells in humans. Therefore, we developed a novel live-cell multiplexed cytokine capture assay to identify, isolate and transcriptionally-profile vaccine-specific polyfunctional CD4⁺ T cells. We applied these methods to samples from subjects who received the RV144 vaccine regimen, as part of the HVTN 097 clinical trial. We identified two surface receptors (CD44 and CD82) upregulated on polyfunctional T cells and a Th2-biased transcriptional signature (*IL-4*, *IL-5*, and *IL-13*) that predicted the envelope-specific polyfunctional CD4⁺ T cell profiles that had correlated with reduced risk of HIV infection in RV144. By linking single-cell transcriptional and functional profiles, we may be able to further define the potential contributions of polyfunctional T cells to effective vaccine-elicited immunity.

^{||}Address correspondence to Raphael.gottardo@chuv.ch.

Author contributions

R.G., S.D., and K.C. conceived the study. K.C., C.T. and A.S. planned and developed the methods, conducted the assays, and analyzed the data. A.S., Y.T. and R.A. conducted formal statistical analyses. K.C., Y.T., C.T. and A.S. drafted the original manuscript; R.G., S.D., M.J.M., and K.C. edited the manuscript. M.J.M., R.G., K.C. and S.D. secured funds and supervised the project. All authors read and approved the manuscript.

Conflict of interest statement

R.G. has received consulting income from Takeda and declares ownership in Ozette Technologies, and Modulus Therapeutics. R.A.A. is an employee and stockholder of Pfizer. The remaining authors have no conflicts of interest to declare.

Introduction

Almost forty years since its identification as the causal agent of AIDS, HIV remains a significant public health challenge. Despite tremendous effort to develop a vaccine to prevent HIV infection, the pox-protein vaccine regimen that was tested for efficacy in the RV144 clinical trial remains the only vaccine, thus far, to have demonstrated vaccine-elicited protection from HIV acquisition, all be it with modest efficacy (1).

As a result of the this ground-breaking achievement, a similar vaccine regimen was developed for use in sub-Saharan Africa which also utilized the ALVAC vector platform, but expressed a different HIV-1 envelope gp120 insert, the subtype C zm96 strain (vCP2438), and the boost was co-administered with different bivalent gp120 proteins and different adjuvant, MF59 instead of alum. Lastly, the modified regimen included an additional vaccination at 1 year post enrollment to improve durability of the vaccine-elicited immunity (2). Notably, this subtype C-adapted RV144-similar pox-protein vaccine regimen was tested in a phase 2b-3 efficacy trial (HVTN 702) to evaluate HIV-1 prevention in populations at-risk in sub-Saharan Africa and it failed to demonstrate any protection against HIV-1 acquisition (3). Thus, the original RV144 vaccine regimen continues to be the only vaccine to have demonstrated vaccine-mediated reduced risk of HIV infection. Thus, further investigation into the vaccine-induced correlates of protection identified in RV144, in particular, continues to be of significant interest to the field.

Utilizing an unbiased, Bayesian statistical approach, referred to as COMPASS, we previously determined that polyfunctional HIV envelope (env)-specific CD4+ T-cell responses correlated with a reduced risk of HIV infection in the RV144 trial (4). Polyfunctional T cells are able to simultaneously produce multiple functions or cytokines and HIV-specific polyfunctional T cells have been repeatedly correlated with improved clinical outcomes in HIV infection (5, 6) and vaccination (7). In particular, two rare subsets of highly polyfunctional env-specific CD4+ T cell profiles: 1) IL-4, IL-2, CD154, IFN- γ , and TNF- α ; and, 2) IL-4, IL-2, and CD154, correlated with reduced risk of HIV infection in Rv144 [odds ratio (OR): 0.57, p=0.006 and OR: 0.63, p=0.013, respectively], when the overall magnitude of env-specific CD4+ T-cell responses by IFN- γ and IL-2 expression did not (4). We sought to better understand the potential mechanism(s) by which these cells might contribute to prevention of HIV-1 infection. We hypothesized that these rare polyfunctional env-specific CD4+ T cells had unique functional properties that were either directly or indirectly correlated with their cytokine expression profiles.

Thus, we sought to determine whether these rare polyfunctional env-specific CD4 T cells had other characteristics that could explain their unique correlation with protection. Therefore, we performed single-cell transcriptional analyses of polyfunctional env-specific CD4+ T cells to gain a deeper understanding of the potential mechanism(s) contributing to protective immune responses induced by the RV144 vaccine regimen. We sought to determine whether there were transcriptional signatures specific to these polyfunctional cells that were vital to vaccine efficacy compared to cells expressing one or two effector functions. However, the intracellular cytokine staining (ICS) methods traditionally used to

identify polyfunctional T cell subsets require fixation and permeabilization, which damages the mRNA and precludes downstream transcriptional analysis. Alternatively, activation induced marker (AIM) assays have been used to identify and enrich antigen-specific T cells for transcriptional analyses (8–10). These assays rely on upregulation of surface markers that are preferentially upregulated after activation. However, the AIM assays do not allow for identification of polyfunctional T cells to be specifically interrogated. In addition, AIM markers have variable baseline expression which effects the specificity of detection of vaccine-specific cells and upregulation of activation markers requires extended incubation times (up to 18 hours), which can alter the transcriptional profiles and cause bystander activation of cells that are not vaccine-specific.

Therefore, we developed a novel multiplexed cytokine capture assay to be able to identify and sort individual, viable, antigen-specific cytokine-expressing CD4⁺ T cells, for single-cell RNA sequencing (scRNA seq). The flow cytometry data was captured for each individual sorted T cell, enabling scRNA sequence data to be linked to the observed cytokine protein expression. The resulting analyses demonstrated that polyfunctional CD4⁺ T cells could be specifically detected among the vaccine-stimulated T cells by the multiplexed cytokine capture assay. It also led to the identification of novel surface-expressed activation markers, CD82 and CD44, which were significantly upregulated among polyfunctional CD4⁺ T cells. Lastly, we established a Th2-biased transcriptional signature predicted the polyfunctional CD4⁺ T cell profiles that had correlated with reduced risk of HIV infection in the RV144 HIV efficacy trial, suggesting that the mechanism of vaccine-induced protection in RV144 was in part due to Th2 functions, likely through support of the humoral response.

Materials and Methods

HVTN 097 phase 1 clinical trial samples

HVTN 097 was a randomized, double-blind, placebo-controlled phase 1b clinical trial of the RV144 vaccine regimen and was conducted in South Africa (11). Vaccine recipients received ALVAC-HIV at month 0 and 1, followed by ALVAC-HIV plus AIDSVAX gp120_{B/E} at months 3 and 6. Peripheral blood mononuclear cells (PBMC) were collected at month 6.5 (2 weeks post fourth/last vaccination) for immunogenicity measurements, which were published previously (11). The study was approved by all appropriate IRBs and all participants provided written consent.

Intracellular Cytokine Staining (ICS) Assay

Flow cytometry was used to examine HIV-1-specific CD4⁺ T cell responses from cryopreserved PBMC as previously described (11). Responses were evaluated to pools of overlapping peptides matched to the HIV-1 vaccine vector insert antigen, 92TH023-env, measured at two weeks after final vaccination. Positivity of the ICS responses of individual cytokines or cytokine combinations was determined by a one-sided Fisher's exact test applied to each peptide pool-specific response versus the negative control response with a discrete Bonferroni adjustment for the multiple comparisons due to testing against multiple peptide pools. Peptide pools with adjusted p-values less than 0.00001 were considered

positive. We selected samples for analysis by capture assay that had a positive response to the env peptide pool in the ICS assay during clinical trial testing.

Multiplexed Cytokine Capture Assay

The multiplex cytokine capture assay is similar to the ICS assay by employing vaccine-specific peptides to induce the secretion of cytokines by vaccine-specific T cells. The catch reagents contain antibodies specific for the cytokines of interest, which adhere to the cell via a proprietary mechanism (Miltenyi Biotec), likely an antibody specific for a surface cell marker expressed on leukocytes, such as CD45, to capture the cytokines as they are secreted by the cell. After the catch reagents have bound to the cell, the cells are diluted and incubated to allow for cytokine secretion from the activated T cells. The cytokines are captured by the catch reagents and tethered to the cell that released the cytokine. The captured cytokines can then be detected by flow cytometry using surface staining methods.

PBMC were thawed quickly in warm RPMI media containing 10% FBS, L-glutamine, penicillin-streptomycin (R10) and rested overnight. An aliquot of cells was stained in Guava ViaCount reagent and counted using a Guava easyCyte (EMD Millipore), then resuspended in R10. The cells were incubated with purified anti-CD40 monoclonal antibody (Miltenyi Biotec) for 10 minutes before being stimulated (12). CD154-PE-Cy7 antibody was added along with 1 $\mu\text{g}/\text{mL}$ anti-human CD28/CD49d co-stimulatory antibodies and either 2 $\mu\text{g}/\text{mL}$ vaccine-matched 92TH023-env peptide pool or with peptide diluent (DMSO) for 5 hours at 37°C 5% CO₂. Cells were washed in cold wash buffer (1× PBS, 2 mM EDTA, 0.5% BSA) and then incubated with 10 μL per 10⁶ cells each of: IFN- γ Catch Reagent (Miltenyi Biotec), IL-2 Catch Reagent (Miltenyi Biotec), IL-4 Catch Reagent (Miltenyi Biotec) in a final volume of 100 μL per 10⁶ cells wash buffer for 15 minutes on ice. Cells were washed with R10 media and then resuspended in a minimum of 1 mL per 10⁶ cells (~10 mL) of warm R10 media and incubated rotating at 37°C 5% CO₂ for 1 hour. Samples were centrifuged and then washed with cold wash buffer and stained with aqua viability dye for 10 minutes on ice. Samples were washed once with cold wash buffer. The cold buffer was decanted. Samples were stained with the antibody cocktail containing lineage and phenotyping markers as well as cytokine detection antibodies and incubated for 20 minutes on ice (Table S1). The samples were washed once more with cold wash buffer. Samples were resuspended in 800 μL of cold buffer and filtered immediately before sorting. Live CD14⁻ CD19⁻ CD56⁻ CD8⁻ CD4⁺ T lymphocytes that were either CD154⁺ IFN- γ ⁺ IL-2⁺, CD154⁺ IL2⁺, or CD154⁺ were single-cell sorted with a FACSAria II cell sorter. Full functional profiles were determined post-sorting using analysis of the individual cell-level flow cytometry data (acquired by indexing).

ICS Assay Including CD44 and CD82

The ICS assay was adapted to include surface staining for CD44 and CD82 (11). In brief, cryopreserved PBMC from a healthy control were thawed quickly in warm R10, washed twice in R10 and rested overnight in a 37°C 5% CO₂. Cells were washed with R10, and resuspended at 5x10⁶/mL in R10 plus 1 $\mu\text{g}/\text{mL}$ anti-human CD28/CD49d co-stimulatory antibodies and either 0.25 $\mu\text{g}/\text{mL}$ staphylococcal enterotoxin B (SEB) or with peptide diluent (DMSO), transferred to a 96-well round bottom plate and incubated for 6 hours

at 37°C 5% CO₂. Then, the cells were stained with the Live/Dead Blue viability dye in 1x PBS for 15 minutes and washed with FACS wash (1× PBS, 2% FBS). The cells were stained with antibodies for CD44 and CD82 and incubated for 15 minutes (Table S1). The cells were washed with FACS wash and then resuspended with 100 μL 1x FACS Lyse (BD Biosciences; #349202) for 10-15 min at room temperature. Then, 100 μL of wash buffer was added and cells were centrifuged, decanted and resuspended with 200 μL of 1X FACS Perm II (BD Biosciences; #340973) and incubated for 10-15 min at room temperature. Wash buffer (100 μL) was added and cells were centrifuged, decanted and resuspended in 50μL of a cocktail of the remaining antibodies in FACS Wash (Table S1). Cells were incubated for 30 minutes at room temperature in the dark and then washed three times with FACS Wash and resuspended in 1% paraformaldehyde in 1x PBS. Cells were collected on a LSRII (BD Biosciences) and data was analyzed using FlowJo v9.9.4.

Single-Cell RNA Sequencing (scRNA seq)

Samples were single-cell sorted into 96-well PCR plates containing 5 μL of DNA Suspension Buffer (Teknova) with 1% BSA (Sigma-Aldrich) per well. Plates were sealed, briefly vortexed, centrifuged at 800 × g for 1 min and immediately transferred to dry ice. Plates were stored at -80°C for at least overnight before proceeding. The plates were thawed on ice and spun at 800 × g for 1 min to collect all liquid. We used a modified version of a previously published method to amplify the whole transcriptome (13). In brief, the reverse transcriptase that is used to make cDNA has a terminal transferase activity. Then, a “template-switch” primer incorporates a second universal priming sequence yielding cDNA with two universal priming sequences.

In brief, reverse transcription occurred in two steps. The initial step was conducted in 5 μL of the lysed cell, 2.4 μM 3' SMART CDS Primer II A (custom primer from IDT), 2.4 mM each dNTP mix (GeneAmp) and 6.32 U RNaseOUT (Invitrogen). The samples were incubated at room temperature for 1 min, 72°C for 3 min and held on ice before beginning the second step. The next step was conducted with SuperScript II Reverse Transcriptase Kit (Invitrogen), using 7 μL of the step 1 product, 1× First Strand Buffer, 2.5 mM DTT, 110 U SuperScript II and an additional 11 U RNaseOUT, as well as 1 μM SMARTer II Oligonucleotide (custom primer from IDT) and molecular-grade water to 11 μL. The samples were incubated at 42°C for 90 min, followed by a limited cycle amplification of 10 cycles at 50°C for 2 min and 42°C for 2 min, concluding with a final extension at 72°C for 15 min.

Whole transcriptome amplification (WTA) immediately proceeded with the 11 μL of the reverse transcription product, using 1× KAPA HiFi HotStart Ready Mix (Roche) and 0.5 μM IS PCR Primer (IDT). Amplification parameters were 98°C for 3 min and 22 cycles of 98°C for 15 sec, 67°C for 20 sec and 72°C for 6 min, followed by a final extension of 72°C for 5 min. The WTA product was cleaned using AMPure XP beads (Beckman Coulter). The PCR product was incubated at room temperature for 5 min with 0.8 volumes of XP beads before being placed on a magnet. The beads were washed three times with 100 μL of 80% ethanol. After briefly drying, the beads were resuspended in 20 μL of 1× TE Buffer (Sigma Aldrich) and 18 μL of supernatant was transferred to a new 96-well PCR plate. Quality

and quantitation were measured by TapeStation using a High Sensitivity D5000 ScreenTape (Agilent).

Samples with a concentration 200 pg/μL were carried forward for sequencing according to the Nextera XT DNA Library Preparation Kit (Illumina) protocol. Samples were dual-indexed using the Nextera Index XT Kit (Illumina) and a scheme that would allow for eight pools without overlapping indices. After pooling, the concentration of each pool was measured by Qubit dsDNA HS Assay Kit (Invitrogen) and sizing was determined by Fragment Analyzer HS Small Fragment Kit (Agilent). A smear analysis was conducted in the range of 150 to 1000 bp, and the average peak size along with the Qubit results were used to determine the molarity. Each pool was then diluted to a concentration of 2 nM. The samples were sequenced on the Illumina HiSeq 2500 using PE50 on a high-output 8-lane flow cell with one pool per lane.

Custom Primer Sequences, 5' to 3'—3' SMART CDS Primer II A [Modified Oligo(dT)]: AAGCAGTGGTATCAACGCAGAGTACT(30)VN

SMARTer II Oligonucleotide [Template Switching Oligo]:
AAGCAGTGGTATCAACGCAGAGTACATrGrGrG

IS PCR Primer [WTA PCR Primer]: AAGCAGTGGTATCAACGCAGAGT

Statistical Methods

scRNA seq analysis—Fastq files were processed with Kallisto v0.45.0 (14), and gene-level counts were generated from abundances scaled using the average transcript length, averaged over samples and to library size (lengthScaledTPM), using the tximport package v1.16.1 (15). Subsequent analysis was performed using a typical Bioconductor workflow (16). Briefly, the count matrix was imported into R to create a SingleCellExperiment object. Cells with a library size of < 30,000 reads were removed from the analysis. After QC metric filtering, a total of 689 cells were kept for downstream analysis. The logNormCounts function from the scater package v1.16.2 (17) was used to generate log-transformed normalized expression values. PCA was performed using the top 4000 highly variable genes, and tSNE (18) and UMAP (19) was subsequently performed using the top 30 principal components for data visualization. The top 30 principal components were also used to build a shared nearest-neighbor (SNN) graph, and cell clusters were identified using the walktrap algorithm from the igraph package v1.2.5 (20). Differentially expressed genes between groups were identified using MAST v1.14.0 (21). Genes with a false discovery rate (FDR) of < 0.05 and a fold change of > 1.25 or < -1.25 were considered significantly differentially expressed between groups.

Predicting cell-level functional phenotypes correlated with decreased HIV risk

We use tree boosting, as implemented in XGBoost (22), to build a non-linear model predicting polyfunctionality from gene expression profiles. The log-transformed normalized expression values of 28,383 genes that were expressed in at least 3 cells were used to train a binary XGBoost classifier using the xgboost Python package v1.1.0 (22) with the following parameters: 'objective': 'multi:softprob', 'num_class': 2, 'n_estimators': 1000,

'n_jobs': 6, 'random_state': 0, 'scale_pos_weight': 5.51, 'subsample': 0.9. The classifier was evaluated using stratified five-fold cross-validation and the Area Under the Receiver Operating Characteristic Curve (ROC AUC) metric. SHAP (Shapley Additive exPlanations) values were calculated using the shap Python v0.37.0 (23).

Data Availability

The accession number for the RNA-sequencing data reported in this paper is Gene Expression Omnibus (GEO): GSE166945 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi>).

Results

Evaluation of vaccine-specific CD4+ T cells by multiplexed cytokine capture assay

We sought to further interrogate the HIV env-specific CD4 T cells induced by the RV144 vaccine regimen however we didn't have access to additional PBMC samples from RV144. Therefore, instead, we leveraged access to samples from a phase I clinical trial, HVTN 097, which tested the same pox-protein vaccine regimen as RV144. HVTN 097 was a phase Ib clinical trial that tested the prime-boost vaccine regimen that was used in the RV144 efficacy trial: ALVAC-gp140 with subtype B insert boosted with the co-administered bivalent subtype B/E gp120 proteins adjuvanted with alum, as described previously (1, 11). One of the primary goals of HVTN 097 was to confirm the immune profiles induced by the RV144 vaccine regimen, originally conducted in Thailand, in a different recipient population, South Africa. Indeed, the RV144 vaccine regimen tested in HVTN 097 induced env-specific polyfunctional CD4+ T cell responses, including the specific subsets: IL-4, IL-2, CD154, IFN- γ , and TNF- α ; and IL-4, IL-2, and CD154 (4), which had correlated with reduced risk of infection in RV144 (11, 24).

To interrogate the transcriptional profiles of these rare subsets of cells, we developed a live-cell multiplexed cytokine capture assay to detect and sort vaccine-specific polyfunctional CD4+ T cells. To detect CD154 (CD40L), we preincubated the cells with antibody against CD40 to block uptake of its ligand, CD154, and then co-cultured the cells with fluorescently-labeled anti-CD154 antibody during the stimulation. Then, we multiplexed cytokine capture reagents to simultaneously detect secreted IFN- γ , IL-2 and IL-4. Due to experimental limitations, we decided to not use TNF- α as it was commonly co-expressed with IFN- γ among the polyfunctional T cell subsets and deemed not critical for distinguishing the env-specific CD4+ T cell "correlate" profiles: IFN- γ , TNF- α , IL-4, IL-2, and CD154 (OR: 0.57, p=0.006) and IL-4, IL-2, and CD154 (OR: 0.63, p=0.013) (4).

We selected HVTN 097 samples (n=6) based on the presence vaccine-induced env-specific CD4+ T cells as determined by IL-2+ and/or IFN- γ + in the ICS assay (median 0.286% of CD4 T cells). The two polyfunctional 'correlate' subsets encompass a very rare population. In this subset of samples, the env-specific T cells with either "correlate" profile were a median of 0.015% of CD4 T cells (range 0.009-0.096%) and median of 2% (range 0.81–7.73%) of the env-specific CD4 T cells, which was consistent with previous studies (11, 24).

Using the multiplexed cytokine capture assay, we single-cell sorted cytokine-positive env-specific CD4+ T cells from PBMCs from HVTN 097 vaccine recipients, 2 weeks post-final

HIV vaccination, for transcriptional profiling by scRNA seq. In general, we were able to detect diverse functional env-specific CD4⁺ T cell responses (Figure 1A and 1B). While there was some monofunctional background in the individual cytokines in the capture assay, the background was low or non-existent among bi-, tri- or polyfunctional subsets (Figure 1A). The magnitudes of env-specific CD154⁺ and IL-4⁺ CD4⁺ T cells were similar between the two assays with no significant differences, whereas frequencies of IL-2⁺ and IFN- γ ⁺ CD4⁺ T cells were higher in the ICS assay compared to the capture assay ($p=0.03$; Figure 1B). The higher IL-2⁺ and IFN- γ ⁺ CD4 T cell frequencies in the ICS assay were likely due to the longer time during which secretory inhibitors allow cytokines to accumulate intracellularly for detection in the ICS assay (6 hours). In contrast, in the multiplexed cytokine capture assay, the cytokine capture reagents are only added for the last hour of the incubation. Detection of secreted cytokines in the multiplexed cytokine capture assay is also limited by the number of the catch reagents bound to the surface of the cell.

CD154 is a surface-expressed T cell activation marker which can be detected by intracellular staining as is done in the ICS assay. In the multiplexed cytokine capture assay, we used co-culture with a fluorophore-labeled anti-CD154 detection antibody. Detection of CD154 by the two methods yielded similar frequencies and represented the single largest population of responding CD4⁺ T cells in both assays (Figure 2B and 2C). In contrast, there were more monofunctional IFN- γ ⁺, IL-2⁺ or IL-4⁺ CD4 T cells detected in the multiplexed cytokine capture assay compared to ICS (Figure 1C and 1D). In general, there was a similar distribution of polyfunctional profiles among env-specific CD4 T cells in the capture assay compared to the ICS assay (Figure 1D). Indeed, the multiplexed cytokine capture assay had reliable detection of diverse polyfunctional vaccine-specific CD4⁺ T cells in each of the samples tested, including the two highly polyfunctional (3 and 4-function) subsets which corresponded to the profiles which correlated with reduced risk of infection in RV144: IFN- γ , IL-4, IL-2, and CD154; and IL-4, IL-2, and CD154 (Figure 1D). Lastly, the multiplexed cytokine capture assay had negligible CD4⁺ T cells expressing 2 or more cytokines in the negative control stimulations indicating the highly specific detection of polyfunctional T cells in the env-stimulated samples (Figure 1A).

Single-cell gene expression analysis of vaccine-induced CD4⁺ T cells with diverse functional profiles

We used a combination of sort criteria in the multiplexed capture assay to single-cell index-sort a diverse representation of cytokine-positive env-stimulated CD4⁺ T cells for transcriptional profiling by scRNA seq. Since the polyfunctional CD4⁺ T cells are very rare, after sorting, we preferentially selected polyfunctional T cells in addition to a random selection of other cytokine-positive T cells for conducting scRNA seq. We conducted reverse transcription using SMART primers which incorporate a universal primer sequence to ensure sensitive and unbiased cDNA synthesis and subsequently amplified the whole transcriptome (13).

We performed scRNA seq on env-specific CD4⁺ T cells with diverse functional profiles from the post-vaccination samples. The distribution of env-specific CD4⁺ T cells ($n=1,423$) for which scRNA seq data was generated included representatives of all the functional

subsets identified by the flow cytometry data (Figure S1A). The largest subset of env-specific CD4⁺ T cells in the scRNA seq dataset was characterized by IL-2 and CD40L protein co-expression. However, this was to be expected as this cell subset was a dominant population among multi-functional subsets in both the ICS and multiplexed cytokine capture assay protein expression data by flow cytometry (Figure 2D). Because of the sorting and sequencing strategy, polyfunctional CD4⁺ T cells, including the subsets that correlated with reduced risk of infection in RV144 as indicated by co-expression of: IFN- γ , IL-4, IL-2, and CD154; or IL-4, IL-2, and CD154 (“correlate”), were enriched in the scRNA seq dataset compared to the absolute frequencies by flow (Figure S1A, 1C and 1D).

We compared the detection of the individual cytokines: IFN- γ , IL-4, IL-2, and CD154 by protein expression and transcript levels (Figure S1B). In all cases, cytokine transcript levels were significantly higher among CD4 T cells that were positive for that cytokine’s protein expression by flow cytometry (Figure S1B). This further supports the specificity of the detection of the cytokines by capture assay. We wouldn’t expect a perfect correlation between transcript and protein expression as there are temporal differences in their expression with peak transcript levels generally preceding peak protein levels.

Using t-Distributed Stochastic Neighbor Embedding (t-SNE), we first looked to see whether dimension reduction analysis could identify gene expression clusters which corresponded to degree of functionality or protein expression of specific cytokines identified by the multiplexed cytokine capture assay (Figure S2). We overlaid the protein functional markers that were detected by flow cytometry on the cells clustered by gene expression. First, we looked by degree of polyfunctionality (or simply the number of functional markers co-expressed by each cell). The clusters defined by overall gene expression did not correspond to degree of polyfunctionality, except for a small distinct island at the top that was predominantly monofunctional. Then, we overlaid the protein expression of each cytokine/functional marker individually and found that once again they did not cluster by gene expression (Figure S2). The only exception being the one monofunctional island of cells that appeared to express only IFN- γ (Figure S2). Lastly, we assessed whether cells with “correlate” functional cytokine profiles would cluster together by gene expression, and we found that they did not (Figure S2). The lack of gene expression clusters corresponding with the functional profiles could be in part because it can be difficult to discern discrete clusters among a population with limited heterogeneity.

Polyfunctional vaccine-specific CD4⁺ T cells have increased expression of genes associated with T helper function

Thus, we looked at differential gene expression analysis using MAST to determine whether there were specific genes whose expression correlated with polyfunctionality. MAST is a generalized linear framework that accounts for the bimodality of scRNA-seq data and is suitable for identifying differentially expressed genes (21). MAST models cellular detection rate as a covariate and can control for differences in abundance due to extrinsic biological and technical effects (21). We compared the monofunctional vs. polyfunctional (i.e., > 1 cytokine/function) vaccine-specific CD4⁺ T cells and discovered 23 genes that were significantly differentially expressed. Interestingly, the top hits included a number of

protein-coding genes upregulated among the polyfunctional T cells and directly linked to CD44 plays a role in cell adhesion and cell-cell interaction and CD82 associates with CD4 and delivers costimulatory signals for the TCR/CD3 pathway. CD4+ T cell function: *CD44*, *CD82*, *IFN- γ* , *IL-2*, *IL-3*, *IL-4*, *IL-5*, and *IL-21* (Figure 2A and B). *IFN- γ* , *IL-2*, *IL-3*, *IL-4*, *IL-5*, and *IL-21* are cytokines with anti-viral or B cell activation, growth, and differentiation activity. Other transcripts that were significantly associated with polyfunctionality included multiple RNA- or protein-coding genes involved in regulation of translation (*DDX21*, *RPL36AL* and *RPL6*), secretory pathway (*CCT8*), and cell cycle/proliferation (*CYTOR*, *HSP90AB1*, and *MIR155HG*) (Figure 2A and B).

CD44 and CD82 were interesting, in particular, because they are both cell surface receptors that are upregulated by T cell activation and may be useful for identifying vaccine-induced polyfunctional T cells. To assess this, we evaluated CD44 and CD82 as part of an ICS assay utilizing PBMC from healthy unvaccinated adult subjects and a polyclonal stimulant, staphylococcal endotoxin B (SEB). We found that CD44 and CD82 were each individually upregulated among the polyfunctional CD4 T cells as compared to the monofunctional CD4 T cells (Figure S3). In addition, 83% of polyfunctional CD4 T cells co-expressed both CD44 and CD82, in comparison to 60% of monofunctional CD4 T cells.

Th2-biased transcriptional signature predicts vaccine-specific CD4+ T cell profile correlated with reduced risk of HIV infection

Next, we compared the gene expression profiles of the cell subsets that had been previously associated with reduced risk of HIV infection in RV144 (“correlate”) compared to all other subsets of cytokine-expressing env-specific CD4+ T cells (“non-correlate”) using MAST. We found 14 genes that were significantly differentially expressed among the env-specific CD4+ T cells with the “correlate” compared to the “non-correlate” functional profiles. In particular, we found that expression of *IL-3*, *IL-4*, *IL-5* and *IL-13* were significantly upregulated among the T cells with the “correlate” functional profile (Figure 3A and B). Genes such as *CD44*, *CD82*, and *IL-21* were not detected as differentially expressed in this analysis, either because the sample size was too small or because they were associated with polyfunctionality and not necessarily with the specific “correlate” phenotypes. Alternative analyses of these specific genes suggested that *IL-21* was also associated with the “correlate” phenotype (FDR adjusted p-value = .15), while *CD44* and *CD82* were not and were instead indicative of overall polyfunctionality (Figure S1C). Other transcripts that were significantly associated with the CD4+ T cells that exhibited the “correlate” functional profiles included protein-coding genes involved in regulation of JAK/STAT cell signaling pathway (*SOCS2*), transcription and/or translation (*BZW1*, *LCMT2* and *ZNF33*), and cell cycle/proliferation (*TTC28*, *WIPF2*) (Figure 3A and B).

Building on this analysis, we asked whether there was a transcriptional signature which could predict the presence of the “correlate” functional profiles, using non-linear boosting trees implemented in XGBoost (22). To avoid overfitting and more accurately evaluate model prediction performance, we conducted 5-fold cross-validation where the data was first split into 5 smaller sets. Subsequently, each unique set was retained as the test data set, and a model was trained using the remaining 4 sets as training data and evaluated on the test

set. The average Area Under the Receiver Operating Characteristic Curve (ROC AUC) for the model was 0.76 with a standard deviation of 0.10 (Figure 4A). We found that expression of *IL-4*, *IL-5*, and *IL-13* were among the top 30 genes which contributed to the prediction of the T cells with the “correlate” profiles (Figure 4B). We further calculated the SHAP (SHapley Additive exPlanations) values of the top 30 genes for every cell averaged across the five models to see which genes contributed to increased/decreased risk of infection (Figure 4C). SHAP values indicate a gene’s impact on a change in the model output (23). As shown in Figure 4C, high expression of *IL-5*, *IL-4*, and to less extent, *IL-13*, drove the model predictions towards the functional profiles correlated with reduced risk of HIV infection. These data suggest that the expression of Th2 cytokines may be uniquely detected in these polyfunctional T cell subsets and that this mechanism may be directly or indirectly associated with an immune-mediated reduced risk of infection observed in RV144.

Discussion

Thus far, RV144 remains the only vaccine trial to show at least partial efficacy at preventing HIV infection. In correlates analyses of RV144, two highly polyfunctional env-specific CD4⁺ T cell subsets correlated with reduced risk of HIV-1 infection (1, 4). Using PBMC samples from participants in the HVTN 097 clinical trial, who received the same vaccine regimen as RV144, we sorted env-specific CD4⁺ T cells using a novel multiplexed cytokine capture assay and conducted scRNA sequencing to interrogate potential mechanisms underlying the contribution of env-specific polyfunctional CD4⁺ T cells to vaccine-elicited immunity in RV144. Importantly, we found that expression of Th2 cytokines was upregulated among vaccine-specific polyfunctional T cells and specifically, in the CD4⁺ T cells that correlated with reduced risk of HIV infection in RV144. We also identified expression of the surface markers, *CD44* and *CD82*, as being significantly upregulated among polyfunctional env-specific CD4⁺ T cells. This study represents the first time that individual polyfunctional vaccine-specific CD4⁺ T cells have been directly linked to their transcriptional profiles *ex vivo* and highlights potential mechanisms associated with different functional subsets of vaccine-specific CD4⁺ T cells.

The identification of the cell surface receptors, CD44 and CD82, as being preferentially upregulated among polyfunctional CD4⁺ T cells suggests that they may serve as useful markers of polyfunctional T cells in future applications. In mice, CD44 is a canonical effector memory marker upregulated in response to antigen-specific activation and then maintained (25, 26). In humans, CD44 modulates migration and extravasation and is upregulated by T cell activation or exposure to inflammatory mediators (27). Similarly, CD82 is associated with adhesion and T cell activation (28). Thus, co-expression of CD44 and CD82 may be useful for identifying vaccine-specific polyfunctional CD4⁺ T cells and may correspond with increased trafficking. While we were able to confirm upregulated protein expression on polyfunctional CD4 T cells with a polyclonal stimulation, in future studies we would like to confirm this in the context of vaccine-specific CD4 T cell responses.

In comparing the gene expression profiles of monofunctional and polyfunctional env-specific CD4⁺ T cells, we also identified an enrichment of genes that correspond to

a number of cytokines: *IFN- γ* , *IL-2*, *IL-3*, *IL-4*, *IL-5*, and *IL-21*. While *IFN- γ* , *IL-2*, and *IL-4* correspond to proteins that were used to identify the polyfunctional T cells, *IL-3*, *IL-5*, and *IL-21* were not part of the capture assay panel and suggest that these functions are preferentially upregulated specifically within the multifunctional CD4⁺ T cells. This is interesting as these cytokines have been difficult to detect *ex vivo* among primary antigen-specific CD4⁺ T cells. In particular, secreted IL-21 has been previously detected after extended (40 hour) *in vitro* stimulation and was associated with improved antigen-specific T helper function supporting both antigen-specific CD8⁺ T cells and B cells (29, 30). Similarly, the Th2 cytokines, IL-5, and IL-13, have been difficult to detect by flow cytometry. The detection of *IL-5* and *IL-13* transcripts among *IL-4* expressing T cells suggests that *IL-4* may be a potential surrogate of additional Th2 cytokine activity.

Additionally, a Th2-biased transcriptional profile including expression of *IL-4*, *IL-5*, and *IL-13*, predicted the env-specific CD4⁺ T cells with the “correlate” phenotype. It has been previously demonstrated that the alum adjuvant tends to drive Th2-biased immune responses to vaccination (31). In contrast, MF59 tends to induce a more balanced ratio of Th1 and Th2 responses (32, 33). This difference in Th1 and Th2 bias was confirmed in a study where a SIV version of the ALVAC-gp140 vaccine regimen was adjuvanted MF59 or alum and compared side by side in the non-human primates model (34). The NHP study recapitulated the low level efficacy seen with the alum-adjuvanted vaccine regimen and predicted the lack of efficacy in the MF59-adjuvanted group. Moreover, they found increased Th1 CD4⁺ T cell responses in the alum adjuvanted group and transcriptional profiles associated with increased IL-13 signaling in the MF59 adjuvanted group (34). Thus, the data presented here are consistent with a Th2-biased immune response from the alum adjuvanted vaccination regimen in RV144 and HVTN 097. It would be interesting to compare this to env-specific CD4⁺ T cells induced by the MF59-containing HVTN 702 regimen.

There are multiple potential limitations of this study including the selection of samples from the HVTN 097 study instead of the case-control subset from the RV144 clinical trial. While HVTN 097 tested the same vaccine regimen as RV144, it was conducted in a different study population. In addition, since HVTN 097 was not an efficacy trial, it was impossible to directly link the observed biomarkers with reduced risk of HIV infection. Another limitation is the study size, while we were able to interrogate thousands of vaccine-specific CD4⁺ T cells, those cells were isolated from only 6 independent subjects. The study is limited by the fact that it was limited to a single vaccine regimen. Future studies should evaluate whether these biomarkers of polyfunctionality and the “correlate” profiles are generalizable to other study populations and vaccine regimens. Lastly, it would be interesting to see the capture assay approach applied to detection of some of the cytokines that were detected in the transcriptomics, such as IL-3, IL-5, IL-13 and IL-21 to confirm that the transcriptional upregulation corresponded to increased cytokine secretion.

This study provides a proof of principle that the multiplex cytokine capture assay can be used to identify, isolate, and further interrogate vaccine-specific polyfunctional CD4⁺ T cells. The single-cell transcriptional profiling independently confirmed the flow cytometric detection of rare unique highly polyfunctional subsets among the vaccine-specific CD4⁺ T cells. The gene expression analyses also identified two cell-surface receptors, CD44

and CD82, associated with T cell activation, which may be useful for enriching for polyfunctional antigen-specific CD4⁺ T cells by flow cytometry. Lastly, we identified a Th2-biased transcriptional profile which was specific to the subset of vaccine-specific CD4⁺ T cells that correlated with reduced risk of HIV infection in the RV144 vaccine trial. These results support the hypothesis that the env-specific polyfunctional CD4⁺ T cells induced by the RV144 vaccine regimen contributed to the reduction in HIV infection by modulating the antibody response through T cell help.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. We thank the participants for volunteering their time and effort to participate in this study. We thank the HVTN 097 protocol leadership team, including Drs. Glenda Gray, Surita Roux, Nicole Grunenberg, Ying Huang, Edith Swann, and Georgia Tomaras for oversight of the clinical trial. We thank the HVTN 097 trial site staff led by Drs. Linda-Gail Bekker, Lulu Nair, Gavin Churchyard, Craig Innes, and Fatima Laher for trial implementation and collecting the samples used in this study. At the Fred Hutchinson Cancer Research Center, we thank Dr. Laura Richert-Spuhler and Stephen Voght for their assistance with the manuscript preparation.

Grant Support

Research reported in this publication was supported by the National Institute of Allergy and Infectious Disease of the National Institutes of Health under award numbers U19AI128914 (RG and MJM) and UM1AI068618 (MJM), as well as through VIDD Initiative awards from the Fred Hutchinson Cancer Research Center (KWC, SCD, and RG).

References

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Prensri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH, and Investigators M-T. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *N Engl J Med* 361: 2209–2220. [PubMed: 19843557]
2. Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ, and Team HP. 2018. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. *Lancet HIV* 5: e366–e378. [PubMed: 29898870]
3. Gray GE, Bekker LG, Laher F, Malahleha M, Allen M, Moodie Z, Grunenberg N, Huang Y, Grove D, Prigmore B, Kee JJ, Benkeser D, Hural J, Innes C, Lazarus E, Meintjes G, Naicker N, Kalonji D, Nchabeleng M, Sebe M, Singh N, Kotze P, Kassim S, Dubula T, Naicker V, Brumskine W, Ncayiya CN, Ward AM, Garrett N, Kistnasami G, Gaffoor Z, Selepe P, Makhoba PB, Mathebula MP, Mda P, Adonis T, Mapetla KS, Modibedi B, Philip T, Kobane G, Bentley C, Ramirez S, Takuva S, Jones M, Sikhosana M, Atujuna M, Andrasik M, Hejazi NS, Puren A, Wiesner L, Phogat S, Diaz Granados C, Koutsoukos M, Van Der Meeren O, Barnett SW, Kanesa-Thasan N, Kublin JG, McElrath MJ, Gilbert PB, Janes H, Corey L, and Team HS. 2021. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. *N Engl J Med* 384: 1089–1100. [PubMed: 33761206]
4. Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H, Hanekom W, Bart PA, Pantaleo G, Tomaras GD, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Michael NL, Kim JH, Robb ML, O'Connell RJ, Karasavvas N, Gilbert P, S CDR, McElrath MJ,

- and Gottardo R. 2015. COMPASS identifies T-cell subsets correlated with clinical outcomes. *Nat Biotechnol* 33: 610–616. [PubMed: 26006008]
5. Owen RE, Heitman JW, Hirschhorn DF, Lanteri MC, Biswas HH, Martin JN, Krone MR, Deeks SG, Norris PJ, and N. C. f. H. A. V. Immunology. 2010. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. *Aids* 24: 1095–1105. [PubMed: 20400885]
 6. Betts MR, Gray CM, Cox JH, and Ferrari G. 2006. Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development. *Expert Rev Vaccines* 5: 505–516. [PubMed: 16989631]
 7. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, and Seder RA. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against *Leishmania major*. *Nat Med* 13: 843–850. [PubMed: 17558415]
 8. Chattopadhyay PK, Yu J, and Roederer M. 2005. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. *Nat Med* 11: 1113–1117. [PubMed: 16186817]
 9. Havenar-Daughton C, Reiss SM, Carnathan DG, Wu JE, Kendric K, Torrents de la Pena A, Kasturi SP, Dan JM, Bothwell M, Sanders RW, Pulendran B, Silvestri G, and Crotty S. 2016. Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique. *J Immunol* 197: 994–1002. [PubMed: 27335502]
 10. Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A, Brassard N, Silvestri G, Routy JP, Havenar-Daughton C, Crotty S, and Kaufmann DE. 2017. Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. *PLoS One* 12: e0186998. [PubMed: 29065175]
 11. Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, Swann EM, Bekker LG, Innes C, Lazarus E, Morris L, Mkhize NN, Ferrari G, Montefiori DC, Shen X, Sawant S, Yates N, Hural J, Isaacs A, Phogat S, DiazGranados CA, Lee C, Sinangil F, Michael NL, Robb ML, Kublin JG, Gilbert PB, McElrath MJ, Tomaras GD, and Corey L. 2019. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. *Sci Transl Med* 11.
 12. Frensch M, Arbach O, Kirchoff D, Moewes B, Worm M, Rothe M, Scheffold A, and Thiel A. 2005. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. *Nat Med* 11: 1118–1124. [PubMed: 16186818]
 13. Trombetta JJ, Gennert D, Lu D, Satija R, Shalek AK, and Regev A. 2014. Preparation of Single-Cell RNA-Seq Libraries for Next Generation Sequencing. *Curr Protoc Mol Biol* 107: 4 22 21-17. [PubMed: 24984854]
 14. Bray NL, Pimentel H, Melsted P, and Pachter L. 2016. Near-optimal probabilistic RNA-seq quantification. *Nat Biotechnol* 34: 525–527. [PubMed: 27043002]
 15. Sonesson C, Love MI, and Robinson MD. 2015. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. *F1000Res* 4: 1521. [PubMed: 26925227]
 16. Amezquita RA, Lun ATL, Becht E, Carey VJ, Carpp LN, Geistlinger L, Marini F, Rue-Albrecht K, Risso D, Sonesson C, Waldron L, Pages H, Smith ML, Huber W, Morgan M, Gottardo R, and Hicks SC. 2020. Orchestrating single-cell analysis with Bioconductor. *Nat Methods* 17: 137–145. [PubMed: 31792435]
 17. McCarthy DJ, Campbell KR, Lun AT, and Wills QF. 2017. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. *Bioinformatics* 33: 1179–1186. [PubMed: 28088763]
 18. van der Maaten L, and Hinton G. 2008. Visualizing Data using t-SNE. *Journal of Machine Learning Research* 9: 2579–2605.
 19. McInnes L, Healy J, and Melville J. 2020. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. *arXiv*.
 20. Csardi G, and Nepusz T. 2006. The igraph software package for complex network research. *InterJournal, Complex Systems* 1695.

21. Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, Slichter CK, Miller HW, McElrath MJ, Prlic M, Linsley PS, and Gottardo R. 2015. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. *Genome Biol* 16: 278. [PubMed: 26653891]
22. Chen T, and Guestrin C. 2016. XGBoost: A Scalable Tree Boosting System. In Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. Association for Computing Machinery, San Francisco, CA, USA.
23. Lundberg SM, Erion G, Chen H, DeGrave A, Prutkin JM, Nair B, Katz R, Himmelfarb J, Bansal N, and Lee SI. 2020. From Local Explanations to Global Understanding with Explainable AI for Trees. *Nat Mach Intell* 2: 56–67. [PubMed: 32607472]
24. Zhao LP, Fiore-Gartland A, Carpp LN, Cohen KW, Roupael N, Fleurs L, Dintwe O, Zhao M, Moodie Z, Fong Y, Garrett N, Huang Y, Innes C, Janes HE, Lazarus E, Michael NL, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, De Rosa SC, Corey L, Gray GE, Seaton KE, Yates NL, McElrath MJ, Frahm N, Tomaras GD, and Gilbert PB. 2020. Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. *PLoS One* 15: e0226803. [PubMed: 31999736]
25. Johnson P, and Ruffell B. 2009. CD44 and its role in inflammation and inflammatory diseases. *Inflamm Allergy Drug Targets* 8: 208–220. [PubMed: 19601881]
26. Budd RC, Cerottini JC, Horvath C, Bron C, Pedrazzini T, Howe RC, and MacDonald HR. 1987. Distinction of virgin and memory T lymphocytes. Stable acquisition of the Pgp-1 glycoprotein concomitant with antigenic stimulation. *J Immunol* 138: 3120–3129. [PubMed: 3106474]
27. Ariel A, Lider O, Brill A, Cahalon L, Savion N, Varon D, and Hershkovich R. 2000. Induction of interactions between CD44 and hyaluronic acid by a short exposure of human T cells to diverse pro-inflammatory mediators. *Immunology* 100: 345–351. [PubMed: 10929056]
28. Shibagaki N, Hanada K, Yamaguchi S, Yamashita H, Shimada S, and Hamada H. 1998. Functional analysis of CD82 in the early phase of T cell activation: roles in cell adhesion and signal transduction. *Eur J Immunol* 28: 1125–1133. [PubMed: 9565351]
29. Schultz BT, Teigler JE, Pissani F, Oster AF, Kranias G, Alter G, Marovich M, Eller MA, Dittmer U, Robb ML, Kim JH, Michael NL, Bolton D, and Streeck H. 2016. Circulating HIV-Specific Interleukin-21(+)/CD4(+) T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions. *Immunity* 44: 167–178. [PubMed: 26795249]
30. Chevalier MF, Julg B, Pyo A, Flanders M, Ranasinghe S, Soghoian DZ, Kwon DS, Rychert J, Lian J, Muller MI, Cutler S, McAndrew E, Jessen H, Pereyra F, Rosenberg ES, Altfeld M, Walker BD, and Streeck H. 2011. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. *J Virol* 85: 733–741. [PubMed: 21047960]
31. Li H, Willingham SB, Ting JP, and Re F. 2008. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. *J Immunol* 181: 17–21. [PubMed: 18566365]
32. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, and Van Nest G. 1995. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. *Pharm Biotechnol* 6: 277–296. [PubMed: 7551221]
33. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammiceli C, Hilbert AK, Brauer V, Banzhoff A, Rappuoli R, Del Giudice G, and Castellino F. 2009. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. *Proceedings of the National Academy of Sciences of the United States of America* 106: 3877–3882. [PubMed: 19237568]
34. Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Cameron M, Keele BF, Shen X, Tomaras GD, Billings E, Rao M, Chung AW, Dowell KG, Bailey-Kellogg C, Brown EP, Ackerman ME, Vargas-Inchaustegui DA, Whitney S, Doster MN, Binello N, Pegu P, Montefiori DC, Foulds K, Quinn DS, Donaldson M, Liang F, Lore K, Roederer M, Koup RA, McDermott A, Ma ZM, Miller CJ, Phan TB, Forthal DN, Blackburn M, Caccuri F, Bissa M, Ferrari G, Kalyanaraman V, Ferrari MG, Thompson D, Robert-Guroff M, Ratto-Kim S, Kim JH, Michael NL, Phogat S, Barnett SW, Tartaglia J, Venzon D, Stablein DM, Alter G, Sekaly RP, and Franchini G. 2016. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. *Nat Med* 22: 762–770. [PubMed: 27239761]

Key Points

- Novel multiplexed assay to isolate polyfunctional T cells for downstream analyses
- Identify surface markers upregulated on vaccine-specific polyfunctional CD4 T cells
- Signature predicts CD4 T cell profile correlated with reduced risk of HIV infection




Figure 1. Comparison of env-specific CD4+ T cell responses post-vaccination by multiplexed cytokine capture and ICS assays.

A) Example of multiplexed cytokine capture assay env and negative control stimulations of PBMC from a HVTN 097 vaccine recipient. Data is gated on CD4+ T lymphocytes (live single, CD56-, CD19-, CD14-, CD3+, CD4+ and CD8-). The Y-axis shows CD154 expression, and the X-axis shows: IFN- γ (left), IL-2 (middle), and IL-4 (right). The percentage in the bottom right of each plot indicates the frequency of cytokine positive events and the percentage in the top right (in red) of each plot is the percentage of CD4 T cells that are co-expressing the indicated cytokine with CD154. B) Background-

subtracted percent of CD4 T cells expressing CD154, IFN- γ , IL-2, and IL-4 for each subject by multiplexed cytokine capture and ICS assays (n=6). Significance determined using Wilcoxon Rank test. * indicates p value < 0.05. C) Pie charts show the median distribution of subsets among the env-specific CD4 T cells. Each pie slice indicates the proportion of env-specific CD4 T cells that expressing those cytokines (indicated in the legend) and color-coded by the degree of polyfunctionality: monofunctional (blue), bi-functional (green), tri-functional (yellow/orange) and quad-functional (red). The pie arc colors allow visualization of the functions expressed by each slice. D) Bar chart of the per subject counts of env-specific CD4+ T cell subsets by functional profile from ICS (out of a median of 556 total number of env-specific CD4+ T cells per subject) or multiplexed cytokine capture assay (out of a median of 1,887 total number of env-specific CD4+ T cells per subject) and color-coded by the degree of polyfunctionality. The red boxes indicate the two subsets that correlated with reduced risk of HIV infection in the RV144 vaccine trial.




Figure 2. Individual genes that are differentially expressed by polyfunctional env-specific CD4 T cells

A) Violin plots of logcounts (log₂-transformed normalized counts plus a pseudo-count of 1) of the genes that were significantly differentially expressed between monofunctional (producing only 1 cytokine/function) and polyfunctional (producing 2 or more cytokines/functions) env-specific CD4⁺ T cells. B) Heatmap of z-scores (mean row-centered log₂-counts per million) of the same differentially expressed genes the clustered by polyfunctionality profile.




Figure 3. Individual genes that are differentially expressed by env-specific CD4 T cells expressing RV144 polyfunctional correlate profile compared to non-correlate env-specific CD4 T cells.

A) Violin plots of logcounts of the scRNA sequences for the 14 significantly differentially expressed genes between among the env-specific CD4⁺ T cells grouped by the cytokine protein expression profiles that correlated with reduced risk of HIV infection in RV144, labeled here as: “correlate” (IL-4⁺, IL-2⁺, CD154⁺, and IFN- γ ⁺; and IL-4⁺, IL-2⁺, and CD154⁺), or “non-correlate”. B) Heatmap of z-scores of the differentially expressed genes the clustered by T cells with “correlate” or “non-correlate” cytokine expression profile.

Genes with false discovery rate (FDR) < 0.05 and fold change of >1.25 or < -1.25 were considered significantly differentially expressed between groups.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. Transcriptional signatures predicted rare env-specific polyfunctional CD4 T cell subsets that had correlated with reduced risk of HIV infection in the RV144 trial.

XGBoost machine learning model was used to determine the genes that best predicted the two cytokine profiles associated with reduced risk of infection in Rv144 (“correlate” profile) versus other env-specific CD4+ T cell subsets (“non-correlate” profile). A) Plot shows Receiver Operating Characteristic (ROC) curves created from 5-fold cross-validation. The blue line depicts the mean across the five models. B) Bar graph of the top 30 most important features based on mean feature importance across the five models. C) SHAP values showing the contribution of each gene within each cell for the top 30 genes. Color indicates the level of gene expression in each cell for the corresponding gene.